Proteinuria in Type 2 Diabetes

Definition and Diagnosis

Microalbuminuria is defined as urinary albumin excretion of 30-299 mg/24h, 30-299 mg/g creatinine on a random spot urine sample, or 20-199 μg/min on a timed collection, according to the American Diabetes Association 1
Clinical albuminuria (macroalbuminuria) is defined as urinary albumin excretion ≥300 mg/24h, ≥300 mg/g creatinine, or ≥200 μg/min, as stated by the American Diabetes Association 1, 2
The European Society of Cardiology recommends that all patients with type 2 diabetes should have both urinary albumin excretion and estimated glomerular filtration rate (eGFR) assessed 3

About 40% of type 2 diabetes patients with microalbuminuria show typical diabetic nephropathy changes on biopsy, while approximately 30% have normal or near-normal biopsy results despite having albuminuria, according to the American Journal of Kidney Diseases 4
A substantial number of patients with type 2 diabetes and proteinuria have little or no diabetic glomerulopathy lesions, as reported by the American Journal of Kidney Diseases 4

The American Diabetes Association recommends that diagnosis of abnormal albumin excretion requires confirmation with 2 of 3 specimens collected within a 3-6 month period 1, 5
Specific assays are needed to detect microalbuminuria because standard hospital laboratory assays for urinary protein are not sufficiently sensitive, as stated by the American Diabetes Association 2

For uncontrolled type 2 diabetes patients with proteinuria but no microalbuminuria, consider non-diabetic kidney disease that may require specific therapy, as suggested by the American Journal of Kidney Diseases 4
The American Diabetes Association recommends aggressive control of blood pressure, glycemia, and other cardiovascular risk factors is essential regardless of the pattern of kidney disease 1

A protein-creatinine ratio of 0.6 g/g clearly exceeds the threshold of 300 mg/g for macroalbuminuria, as defined by the American Heart Association, indicating significant proteinuria 6, 7
Creatinine of 1.8 mg/dL indicates Stage 3 chronic kidney disease, characterized by moderately decreased GFR, according to the National Kidney Foundation 8
The combination of elevated creatinine and albuminuria defines chronic kidney disease in diabetic patients, as stated by the American Heart Association 6, 7

The American Diabetes Association recommends targeting HbA1c <7% to reduce microvascular complications, with each 10 mmHg decrease in systolic BP reducing diabetes-related mortality by 15% and microvascular complications by 13%, as reported by the American Heart Association 7
Annual assessment of both urinary albumin excretion and eGFR is mandatory, according to the National Kidney Foundation, to monitor disease progression 8
Consider nephrology referral given Stage 3 CKD, especially if uncertainty about etiology, difficult management issues, or progression to Stage 4, as recommended by the National Kidney Foundation 8

Diabetic nephropathy patients with heavy proteinuria have significantly worse renal outcomes, and cardiovascular mortality risk is substantially elevated, as reported by the American Heart Association 6, 7

The American Diabetes Association recommends initiating dual antihypertensive therapy with an ACE inhibitor or ARB (titrated to maximum tolerated dose) plus a second agent, aggressively targeting blood pressure <130/80 mmHg, and intensifying glycemic control while monitoring renal function closely in patients with severe proteinuria and uncontrolled diabetes and hypertension 9
The European Society of Cardiology suggests that with uncontrolled hypertension and severe proteinuria, two antihypertensive medications should be initiated simultaneously rather than sequential monotherapy 9
An ACE inhibitor or ARB must be the foundation of therapy, titrated to the maximum tolerated dose indicated for blood pressure treatment, as this is first-line for patients with albumin-creatinine ratio ≥300 mg/g 9
A thiazide-like diuretic or dihydropyridine calcium channel blocker should be added as the second agent to achieve blood pressure control 9

The American Heart Association and European Society of Cardiology recommend aiming for blood pressure <130/80 mmHg in diabetic patients with severe proteinuria 9, 10, 11
Some evidence suggests that even lower targets (<125/75 mmHg) may provide additional renoprotection when proteinuria exceeds 1 g/day 10

The American Diabetes Association recommends monitoring serum creatinine, eGFR, and potassium within 1-2 weeks after initiating ACE inhibitor/ARB therapy, and continuing monitoring labs at least annually 9

The European Society of Cardiology suggests implementing weight reduction strategies if the patient is overweight, as this improves both blood pressure and proteinuria 11
Increasing physical activity as tolerated is also recommended 9

The American Diabetes Association advises against combining ACE inhibitor with ARB in patients with severe proteinuria and uncontrolled diabetes and hypertension, as dual RAS blockade increases risk of hyperkalemia, syncope, and acute kidney injury without added cardiovascular benefit 9
Multiple drugs will be required to achieve blood pressure goal; adding additional agents should not be delayed 9, 11

The European Society of Cardiology recommends considering statin therapy and antiplatelet therapy as part of integrated cardiovascular risk reduction in patients with severe proteinuria, diabetes, and hypertension 11